These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9883002)

  • 1. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium.
    Mauser-Bunschoten EP; de Goede-Bolder A; Wielenga JJ; Levi M; Peerlinck K
    Neth J Med; 1998 Dec; 53(6):249-55. PubMed ID: 9883002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa.
    Eichinger S; Lubsczyk B; Kollars M; Traby L; Zwiauer K; Gleiss A; Quehenberger P; Kyrle PA
    Eur J Clin Invest; 2009 Aug; 39(8):707-13. PubMed ID: 19490067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors.
    Mauser-Bunschoten EP; Koopman MM; Goede-Bolder AD; Leebeek FW; van der Meer J; van Marwijk Kooij GM; van der Linden PW;
    Haemophilia; 2002 Sep; 8(5):649-56. PubMed ID: 12199674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
    Hay CR; Negrier C; Ludlam CA
    Thromb Haemost; 1997 Dec; 78(6):1463-7. PubMed ID: 9423795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: advantages of administration by continuous infusion over bolus intermittent injections.
    Scaraggi FA; De Mitrio V; Marino R; Speciale V; Di Bari L; Petronelli M; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Jan; 10(1):33-8. PubMed ID: 10070833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
    Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF
    Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
    Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
    Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
    Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
    Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
    Takedani H; Kawahara H; Kajiwara M
    Haemophilia; 2010 Mar; 16(2):290-5. PubMed ID: 19925628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous infusion of coagulation factor concentrates during intensive treatment.
    Holme PA; Tjønnfjord GE; Batorova A
    Haemophilia; 2018 Jan; 24(1):24-32. PubMed ID: 28873263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
    Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
    J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.
    O'Connell N; Mc Mahon C; Smith J; Khair K; Hann I; Liesner R; Smith OP
    Br J Haematol; 2002 Mar; 116(3):632-5. PubMed ID: 11849223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Continuous infusion of recombinant activated factor VII during and after elbow arthroplasty in a hemophilia A patient with inhibitors].
    Nakamura M; Terashima K; Takashima Y; Amano K; Horikoshi Y; Mimaya J
    Rinsho Ketsueki; 2002 Mar; 43(3):183-8. PubMed ID: 11979750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.
    Morfini M
    Eur J Haematol; 2016 Feb; 96(2):111-8. PubMed ID: 26172449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
    Pruthi RK; Mathew P; Valentino LA; Sumner MJ; Seremetis S; Hoots WK;
    Thromb Haemost; 2007 Oct; 98(4):726-32. PubMed ID: 17938794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
    Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.